# Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis

> **NCT02603146** · PHASE2 · TERMINATED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 144 (actual)

## Conditions studied

- Healthy Participants
- Rheumatoid Arthritis (RA) Prevention

## Interventions

- **DRUG:** Hydroxychloroquine
- **DRUG:** HCQ Placebo

## Key facts

- **NCT ID:** NCT02603146
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-04-27
- **Primary completion:** 2022-11-01
- **Final completion:** 2022-11-01
- **Target enrollment:** 144 (ACTUAL)
- **Why stopped:** Enrollment was closed before reaching the target. In the 1st interim analysis after enrollment closure, the follow up \& treatment of active participants were stopped early due to evidence of futility.
- **Last updated:** 2025-06-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02603146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02603146, "Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02603146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*